177 related articles for article (PubMed ID: 17611569)
1. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine.
Raj K; John A; Ho A; Chronis C; Khan S; Samuel J; Pomplun S; Thomas NS; Mufti GJ
Leukemia; 2007 Sep; 21(9):1937-44. PubMed ID: 17611569
[TBL] [Abstract][Full Text] [Related]
2. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
Grövdal M; Karimi M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engström LM; Kjeldsen L; Linder O; Nilsson L; Olsson A; Holm MS; Tangen JM; Wallvik J; Oberg G; Hokland P; Jacobsen SE; Porwit A; Hellström-Lindberg E
Br J Haematol; 2010 Aug; 150(3):293-302. PubMed ID: 20497178
[TBL] [Abstract][Full Text] [Related]
3. Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine.
Martín I; Navarro B; Serrano A; Villamón E; Calabuig M; Solano C; Chaves FJ; Yagüe N; Orts M; Amat P; Fuentes A; Seda E; García F; Hernández-Boluda JC; Tormo M
Ann Hematol; 2020 Mar; 99(3):527-537. PubMed ID: 31989250
[TBL] [Abstract][Full Text] [Related]
4. [p15(INK4B) methylation on prognosis and response to decitabine in patients with MDS].
Zhang Y; Song LX; Wu LY; Chang CK; Li X
Zhonghua Xue Ye Xue Za Zhi; 2013 Mar; 34(3):237-41. PubMed ID: 23683424
[TBL] [Abstract][Full Text] [Related]
5. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation.
Tien HF; Tang JH; Tsay W; Liu MC; Lee FY; Wang CH; Chen YC; Shen MC
Br J Haematol; 2001 Jan; 112(1):148-54. PubMed ID: 11167795
[TBL] [Abstract][Full Text] [Related]
6. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia.
Cechova H; Lassuthova P; Novakova L; Belickova M; Stemberkova R; Jencik J; Stankova M; Hrabakova P; Pegova K; Zizkova H; Cermak J
Neoplasma; 2012; 59(2):168-74. PubMed ID: 22248274
[TBL] [Abstract][Full Text] [Related]
9. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
[TBL] [Abstract][Full Text] [Related]
10. Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome.
Grövdal M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engström LM; Kjeldsen L; Linder O; Nilsson L; Olsson A; Wallvik J; Tangen JM; Oberg G; Jacobsen SE; Hokland P; Porwit A; Hellström-Lindberg E
Clin Cancer Res; 2007 Dec; 13(23):7107-12. PubMed ID: 18056190
[TBL] [Abstract][Full Text] [Related]
11. Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome.
Yang Y; Zhang Q; Xu F; Chang C; Li X
Eur J Haematol; 2012 Dec; 89(6):469-77. PubMed ID: 23005040
[TBL] [Abstract][Full Text] [Related]
12. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment.
Daskalakis M; Nguyen TT; Nguyen C; Guldberg P; Köhler G; Wijermans P; Jones PA; Lübbert M
Blood; 2002 Oct; 100(8):2957-64. PubMed ID: 12351408
[TBL] [Abstract][Full Text] [Related]
13. Quantitative comparison of CDKN2B methylation in pediatric and adult myelodysplastic syndromes.
Kim M; Kook H; Park HJ; Ahn HS; Lee KC; Lee KS; Park SK; Lim JY; Kim HK; Han DK; Lee DS;
Acta Haematol; 2013; 130(2):115-21. PubMed ID: 23571652
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome.
Diamantopoulos PT; Kontandreopoulou CN; Symeonidis A; Kotsianidis I; Pappa V; Galanopoulos A; Vassilakopoulos T; Dimou M; Solomou E; Kyrtsonis MC; Siakantaris M; Angelopoulou M; Kourakli A; Papageorgiou S; Christopoulou G; Roumelioti M; Panayiotidis P; Viniou NA;
Ann Hematol; 2019 Jun; 98(6):1383-1392. PubMed ID: 30877373
[TBL] [Abstract][Full Text] [Related]
15. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Kantarjian H; Oki Y; Garcia-Manero G; Huang X; O'Brien S; Cortes J; Faderl S; Bueso-Ramos C; Ravandi F; Estrov Z; Ferrajoli A; Wierda W; Shan J; Davis J; Giles F; Saba HI; Issa JP
Blood; 2007 Jan; 109(1):52-7. PubMed ID: 16882708
[TBL] [Abstract][Full Text] [Related]
16. [Detection of methylation levels of multi-genes by real-time PCR in patients with myelodysplastic syndrome].
Wang YC; DU X; Geng SX; Li YY; Weng JY; Lu ZS; Zhong LY; Deng CX; Lai PL; Huang X
Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):254-8. PubMed ID: 21569709
[TBL] [Abstract][Full Text] [Related]
17. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
[TBL] [Abstract][Full Text] [Related]
18. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Hackanson B; Robbel C; Wijermans P; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
[TBL] [Abstract][Full Text] [Related]
19. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression.
Quesnel B; Guillerm G; Vereecque R; Wattel E; Preudhomme C; Bauters F; Vanrumbeke M; Fenaux P
Blood; 1998 Apr; 91(8):2985-90. PubMed ID: 9531610
[TBL] [Abstract][Full Text] [Related]
20. Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities.
Wanquet A; Prebet T; Berthon C; Sebert M; Roux C; Kulasekararaj A; Micol JB; Esterni B; Itzykson R; Thepot S; Recher C; Delaunay J; Dreyfus F; Mufti G; Fenaux P; Vey N
Am J Hematol; 2015 Oct; 90(10):859-63. PubMed ID: 26113240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
